Holen Sie sich die Stockscreener-App
58.39
0.78%
0.45
Schlusskurs vom Vortag:
$57.94
Offen:
$58.11
24-Stunden-Volumen:
1.98M
Relative Volume:
0.85
Marktkapitalisierung:
$14.47B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
19.35
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
+0.40%
1M Leistung:
-0.24%
6M Leistung:
+33.07%
1J Leistung:
+41.21%
1-Tages-Spanne:
$57.94
$58.97
1-Wochen-Bereich:
$57.51
$61.14
52-Wochen-Spanne:
$33.76
$61.14
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
58.39 | 14.41B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
(EXEL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exelixis, Inc. (EXEL) stock price, news, quote and history - uk.finance.yahoo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - FXEmpire
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance Australia
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension - webull.com
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - Yahoo Finance
Exelixis (EXEL) Gains Ground: Shares Rise 1.63% to $58.15 as Buyers Hold Mid-Range SupportSize Factor - siam.in
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Exelixis (EXEL) Slips 0.22% to $58.36, Key Support and Resistance in FocusRisk Reward Setups - careplusvn.com
Exelixis (EXEL) Institutional Ownership 2026 $EXEL - MarketBeat
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B - Yahoo Finance
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? - finance.yahoo.com
Exelixis Inc (EX9.MU) Stock Price, News, Quote & History - Yahoo Finance
Exelixis Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle - Yahoo Finance
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) - Seeking Alpha
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Potential Amidst a Competitive Biotech Landscape - DirectorsTalk Interviews
Analysts Offer Insights on NA Companies: Exelixis (EXEL) and HEICO (HEI) - The Globe and Mail
Exelixis FDA Delay Moves Zanzalintinib Decision to March 2027 - TechStock²
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value - webull.com
Form 8K Exelixis Inc For: 11 September By Investing.com - Investing.com Australia
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term - Stocktwits
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug - Investor's Business Daily
FDA extends review of Exelixis drug application for metastatic colorectal cancer - Investing.com Nigeria
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
EXEL Looks 21.5% Overvalued on GF Value™ as PDUFA Delay Sparks Volatility - GuruFocus
FDA extends review of Exelixis’ colorectal cancer drug candidate - endpoints.news
US FDA extends review of Exelixis’ cancer drug - WSAU
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 - AllSci
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months - Yahoo Finance
US FDA extends review of Exelixis' cancer drug - Reuters
Why is Exelixis stock sliding today? By Investing.com - Investing.com Canada
Exelixis stock falls as FDA extends zanzalintinib review By Investing.com - Investing.com South Africa
Exelixis stock falls as FDA extends zanzalintinib review - investing.com
EXEL Looks 24.3% Overvalued on GF Value™ - GuruFocus
Form 8K Exelixis Inc For: 11 September - Investing.com India
FDA Extends Review Timeline for Exelixis Cancer Drug - TipRanks
U.S. FDA extends review of Exelixis' cancer drug - Yahoo Finance
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules - Yahoo Finance
La FDA américaine prolonge l'examen du médicament anticancéreux d'Exelixis - TradingView
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):